Thursday 12 April 2018 (-1st Week, Trinity Term)

• 12:00 - Anti-hypoxia/HIF-1alpha and Anti-A2A- adenosinergic Co-Adjuvants to enable the rejection of the most resistant to therapies hypoxic and adenosine-rich tumors:
  Dr. Michail Sitkovsky (Northeastern University, Boston)